Lu, Zhihao
Zhang, Xiaotian
Liu, Wei
Liu, Tianshu
Hu, Bing
Li, Wei
Fan, Qingxia
Xu, Jianming
Xu, Nong
Bai, Yuxian
Pan, Yueyin
Xu, Qing
Bai, Wei
Xia, Li
Gao, Yong
Wang, Wenling
Shu, Yongqian
Shen, Lin http://orcid.org/0000-0002-8798-4756
Funding for this research was provided by:
Shanghai Roche Pharmaceuticals Ltd., China
Haiyao Ltd.
Article History
Received: 24 August 2017
Accepted: 7 February 2018
First Online: 27 February 2018
Compliance with ethical standards
:
: The authors have declared no conflicts of interest. This work was supported by Shanghai Roche Pharmaceuticals Ltd., China and Haiyao Ltd. This study is an investigator initiated study. Roche Ltd. provided the drug capecitabine and part of funding. Haiyao Ltd. provided part of paclitaxel. These two corporations played no role in study design, data collection, data analysis, data interpretation.
: The study protocol was approved by the institutional review board of Peking University Cancer Hospital and respective independent ethics committees at each investigating site. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.
: All participants included in the study provided written informed consent.